Home > Boards > Free Zone > User's Groups > TBPT Traders Benefit Planning Tools

OT: Report: Marsh Find Buyer for Putnam

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
EZ2 Member Profile
 
Followed By 203
Posts 219,396
Boards Moderated 1
Alias Born 03/31/01
160x600 placeholder
Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
By Stephen Nakrosis
Dish Network Files FCC Complaint Against Tegna -- Update
Corn Higher on Strong Spot Demand - Daily Grain Highlights
Top Company News of the Day
Front Month Nymex Natural Gas Fell 7.78% to Settle at $4.9890 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.01% to Settle at $2.4866 -- Data Talk
Housing Starts and Existing Home Sales on the Docket -- Data Week Ahead Update
Apple Launching HomePod Mini Speaker, New Line of AirPods
Grains Traders Look to USDA for Guidance; Sugar Trapped in Narrow Range
Adamis Pharma Shares Rise 16% After FDA Approves Zimhi for Opioid Overdose
Avadel Pharmaceuticals Shares Drop 14% After FDA Notification
STOXX Europe 50 Index Ends 0.58% Lower at 3607.17 -- Data Talk
EURO STOXX 50 Index Ends 0.75% Lower at 4151.40 -- Data Talk
STOXX Europe 600 Index Ends 0.50% Lower at 467.04 -- Data Talk
FTSE 100 Index Ends 0.42% Lower at 7203.83 -- Data Talk
DAX Ends 0.72% Lower at 15474.47 -- Data Talk
CAC 40 Index Ends 0.81% Lower at 6673.10 -- Data Talk
Dish Network Files FCC Complaint Against Tegna
FTSE Closed Down Due to Concerns Over Rising Energy Prices, and China's Low 3Q Numbers
Medtronic Plc Down Over 5%, On Pace for Largest Percent Decrease Since June 2020 -- Data Talk
Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
Interactive Brokers Launches Cryptocurrency Trading
Molecular Templates: Vertex Terminates Collaboration
Omeros Shares Tumble as FDA Turns Away Narsoplimab Application
U.S. Home-Builder Sentiment Rose in October on Strong Demand -NAHB
U.S. Industrial Production Fell in September as Supply-Chain Woes, Ida Hit Activity
Becton, Dickinson Unveils ESG Strategy for 2030
Avidity Biosciences Lead Program Gets FDA Fast-Track Designation
EZ2   Monday, 01/01/07 05:31:17 AM
Re: None
Post # of 44 
OT: Report: Marsh Find Buyer for Putnam
Friday December 29, 11:28 am ET
By Eileen Alt Powell, AP Business Writer
Report: Marsh Picks Canadian Company As Likely Buyer for Mutual Fund Div. Putnam Investments

NEW YORK (AP) -- Marsh & McLennan Companies Inc., the nation's largest insurance broker, has selected a buyer for its Putnam Investments mutual funds and investment management division, according to a report Friday.
New York-based Marsh & McLennan had reached an "agreement in principle" to sell the unit for $3.9 billion to Power Corp. of Canada, a Montreal-based company that controls one of Canada's leading mutual fund firms, IGM Financial Inc., the Wall Street Journal reported.

A spokesman for Marsh & McLennan declined comment on the report, as did Nancy Fisher, a spokeswoman for Putnam Investments, which operates out of Boston.

An official with Investors Group Inc., a division of IGM Financial, also refused to discuss the report, saying "We don't comment on rumors and speculation."

But people familiar with the negotiations said the Journal report was accurate.

Earlier this month, Marsh & McLennan's chief executive, Michael G. Cherkasky, told an investor's conference he expected a decision on the sale of Putnam by the end of 2006, but acknowledged the timetable could slip into 2007.

Marsh & McLennan has been under pressure to spin off at least one of its businesses since 2005, when it agreed to pay $850 million to settle allegations of bid rigging and price fixing in the sale of property and casualty insurance to businesses. Part of the settlement was an agreement by Marsh & McLennan to stop accepting special commissions, which has reduced its operating revenue and hurt profitability.

Donald Light, senior analyst with Celent, a Boston-based financial research and consulting firm, said the report on the Putnam deal suggested that Marsh & McLennan was doing well on the sale.

"The reported price, $3.9 billion is on the high side," Light said in a research note. "So the winner here might be Marsh & McLennan. It can use the extra capital to continue finding ways to restore the profit margins of its Marsh brokerage unit, and to rebuild the margins of its Mercer employee benefits group."

If Putnam is sold, Marsh & McLennan will be left with three major divisions: Marsh risk and insurance services, Kroll risk consulting and technology, and Mercer Human Resource Consulting.

The deal still must be approved by Putnam employees who own shares in the company, Putnam mutual-fund shareholders and the board that oversees the funds, the Journal said.

Other companies reportedly interested in Putnam were Amvescap PLC of the United Kingdom and UniCredito Italiano SpA of Italy.

Putnam had regulatory problems of its own. The company paid more than $190 million to settle federal and state investigations launched in 2003 into mutual fund trading abuses.

Investors upset with the market-timing scandal pulled their assets out of Putnam accounts, reducing the Boston-based mutual fund company's holdings from $251 billion at the end of 2002 to $182 billion at the end of September. After months of declines, the company announced its first positive investment inflows in October, boosting assets under management to $187 billion.

Putnam employs more than 3,000, mostly in the Boston area.

AP Business Writer Mark Jewell in Boston contributed to this report.

http://www.mmc.com

http://www.igmfinancial.com





The Precious Present
Spencer Johnson
http://www.livinglifefully.com/flo/flopreciouspresent.htm
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences